Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inflammatory bowel diseases].

C Felley1, J Guyot, J Hess

  • 1Service de gastro-entérologie et d'hépatologie CHUV, 1011 Lausanne.

Revue Medicale Suisse
|March 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatially resolved micromechanical characterisation of human testis tissue reveals distinct signatures across developing, adult and pathological tissue states.

Bioactive materials·2026
Same author

The attribution of human health outcomes to climate change: a transdisciplinary guidance document.

Climatic change·2025
Same author

"Mothers get really exhausted!" The lived experience of pregnancy in extreme heat: Qualitative findings from Kilifi, Kenya.

Social science & medicine (1982)·2023
Same author

Complications and satisfaction in transwomen receiving breast augmentation: short- and long-term outcomes.

Archives of gynecology and obstetrics·2022
Same author

Biopsy-derived oral keratinocytes - A model to potentially test for oral mucosa radiation sensitivity.

Clinical and translational radiation oncology·2022
Same author

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.

ESMO open·2022
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
See all related articles

Non-steroidal anti-inflammatory drugs can worsen inflammatory bowel disease. Pre-operative use of steroids, immunomodulators, or infliximab does not increase surgical complications, but hepatitis B screening is recommended before infliximab treatment.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Context:

  • Inflammatory bowel disease (IBD) management involves various therapeutic agents.
  • Surgical interventions are common in IBD treatment.
  • Understanding drug-induced complications and treatment efficacy is crucial.

Purpose:

  • To review the safety and efficacy of different therapeutic agents in inflammatory bowel disease.
  • To assess the impact of pre-operative treatments on surgical outcomes.
  • To highlight emerging therapies for ulcerative colitis.

Summary:

  • COX-2 specific anti-inflammatory agents may exacerbate inflammatory bowel disease flares, similar to traditional agents.
  • Pre-operative administration of steroids, immunomodulators, or infliximab does not elevate post-operative complication risks.

Related Experiment Videos

  • Hepatitis B reactivation is a risk with infliximab, necessitating pre-treatment screening.
  • Adalimumab, a TNF-alpha inhibitor, shows efficacy in patients unresponsive or intolerant to infliximab.
  • Leucoapheresis presents a promising therapeutic option for ulcerative colitis.

    • Impact:

    • Informs clinical practice regarding the appropriate use of anti-inflammatory and immunomodulatory drugs in IBD patients undergoing surgery.
    • Emphasizes the importance of viral screening prior to biologic therapy to prevent serious infections.
    • Highlights the potential of new biologic agents and apheresis techniques in managing refractory IBD.